Targeted Medical Pharma Inc. – Trademark Portfolio
Entity Type: 03
Targeted Medical Pharma Inc. holds 28 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 27 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 11 trademarks are registered. Notable registered marks include APPTRIM, PERCURA, GABADONE, APPTRIM-D, and CLEARWAYZ. The owner is based in Los Angeles, CA.
Suite 100
2980 Beverly Glen Circle
Los Angeles, CA 90077
Showing of trademarks Trademarks
Trademark Classifications
Targeted Medical Pharma Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Targeted Medical Pharma Inc. have?
Targeted Medical Pharma Inc. has 28 U.S. trademarks filed with the USPTO. Of these, 11 registered, 10 abandoned, 7 cancelled.
What trademark classes does Targeted Medical Pharma Inc. file in?
Targeted Medical Pharma Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Targeted Medical Pharma Inc.'s most well-known trademarks?
Targeted Medical Pharma Inc.'s registered trademark portfolio includes well-known marks such as APPTRIM, PERCURA, GABADONE, APPTRIM-D, and CLEARWAYZ. These are among 11 currently registered trademarks in the portfolio.
What is Targeted Medical Pharma Inc.'s trademark registration success rate?
Targeted Medical Pharma Inc. has a 39% trademark registration rate, with 11 out of 28 resolved applications resulting in successful registration. Currently, 0 applications are pending review.